Karin, M., et al. 2004. Nat. Rev. Drug Dis. 3, 17; Greten, F.R., and Karin, M. 2004. Cancer Lett. 206, 193; Jones, W.K., et al. 2003. Cardiovasc. Toxicol. 3
229; Richmond, A. 2002. Nat. Rev. Immunol
C5176 M y n/d n/d
204 Cytokeratin CK5 C7785 M y n/d n/d
205 Cytokeratin peptide 7 C6417 M y n/d n/d
206 Cytokeratin 8.12 C7034 M y n/d n/d
207 Cytokeratin 8.13 C6909 M y n/d n/d
208 Cytokeratin peptide 13
, C.; Yoo, J.; Atala, A. Nat. Biotechnol.
2016, 34 (3), 312–319.
Figure 3. In-house-developed combinatory bioprinting technology: A)
view of the Hybprinter machine, B) FDM module and SLA vat of Hybprinter
, C.; Yoo, J.; Atala, A. Nat. Biotechnol.
2016, 34 (3), 312–319.
Figure 3. In-house-developed combinatory bioprinting technology: A)
view of the Hybprinter machine, B) FDM module and SLA vat of Hybprinter
3875 KRT18 NP_954657.1 M y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 NP_005547.3 M y n/d n/d
206 Cytokeratin 8.12 C7034 3866, 3860, 3868 KRT15,KRT16,KRT13 NP_002266.2,NP_705694.2,NP_005548.2 M y n